FDA clears Great Smokies' intestinal permeability test:
This article was originally published in Clinica
Great Smokies Diagnostic Laboratory (GSDL) has received US FDA 510(k) clearance for its non-invasive test for measuring intestinal permeability, a measurement used to help diagnose gastrointestinal malabsorption syndromes, such as coeliac disease, Crohn's disease and irritable bowel syndrome. The intestinal permeability test kit is more sensitive than the existing d-xylose test, said the Asheville, North Carolina-based company, which also noted that it was the first commercial laboratory to offer intestinal permeability testing.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.